NASDAQ · INMB
INmune Bio Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for INMB: Nov 05, 2026
INmune Bio Inc. Common stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. The reported EPS for the same quarter last year was $-0.24.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · The Motley Fool · MarketBeat- Fintel · Oct 29, 3:22 PM EDTINmune Bio, Inc. Enters Securities Purchase Agreement for $4.5 million Registered Direct OfferingOn October 27, 2026, INmune Bio, Inc. entered into a securities purchase agreement with a single investor, pursuant to which the company agreed to issue and sell 3,000,000 shares of its common stock at an offering price of $1.50 per share in a registered direct offering. In a con
- Fintel · Oct 21, 4:34 PM EDTINmune Bio Establishes Global Commercialization Framework and Updates Regulatory Strategy for Ebstrocel™INmune Bio, Inc. announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal ce
- RTTNews · Oct 14, 10:18 AM EDTINmune Bio, QCi Partner To Explore New XPro Indications Using Quantum Computing; Stock Up(RTTNews) – INmune Bio Inc. (INMB) and Quantum Computing Inc. (QUBT) announced a collaboration to apply quantum computing, artificial intelligence and data analytics to identify new potential applications for XPro (XPro1595), INmune Bio's investigational treatment for Alzheimer's
- RTTNews · Sep 15, 4:11 AM EDTINmune Bio Adds Rare Disease, Biopharma Executives Duane Clark And James Sapirstein To Board(RTTNews) – ImmuneBio Inc. (INMB), a late-stage immunology company, announced the appointment of R. Duane Clark II and James Sapirstein to its Board of Directors. According to the company, the appointments enhance INmune Bio's commercial and strategic leadership as it advances Eb
- RTTNews · Aug 27, 12:41 AM EDTINmune Submits EMA Regulatory Packages For Ebstrocel In Recessive Dystrophic Epidermolysis Bullosa(RTTNews) – INmune Bio, Inc. (INMB), a late-stage biotechnology company, announced the submission of Orphan Drug Designation and pre-Marketing Authorization Application (MAA) Scientific Advice packages to the European Medicines Agency (EMA) for Ebstrocel, an investigational cell
- RTTNews · Aug 7, 11:17 AM EDTINmune Q2 Loss Narrows, Plans Ebstrocel MHRA Filing In Q4; Stock Up(RTTNews) – INmune Bio Inc. (INMB) Friday announced narrower net loss for the second quarter ended June 30, 2026, owing to absence of a $16.5 million impairment charge, compared to the prior year. The late-stage biotech company also provided several clinical updates for the quart
- The Motley Fool · Aug 7, 2:11 AM EDTINmune Bio (INMB) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 6, 11:03 PM EDTINmune Bio Q2 Earnings Call HighlightsINmune Bio (NASDAQ:INMB) outlined plans to file for conditional approval of its Ebstrocel cell therapy in the United Kingdom by the end of the third quarter or early in the fourth quarter of 2026, while reporting a narrower second-quarter net loss and cash runway into the second
- RTTNews · Aug 3, 8:04 AM EDTINmune Bio Receives $4.6 Mln In Total Rebates; To Advance CORDStrom And XPro1595(RTTNews) – INmune Bio Inc. (INMB), a late-stage biotechnology company, announced on Friday the receipt of a research and development cash rebate from Australia on July 30, 2026, amounting to about $4.2 million.
- RTTNews · Jul 10, 12:10 PM EDTWeekly Buzz: JNJ, VERA Get FDA Nod; VRTX Snaps Up CRNX; MSLE Aces DMD Trial; IONS Misses Key Goal(RTTNews) – This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech and pharmaceutical sectors.
- RTTNews · Jul 9, 7:55 AM EDTINmune Bio Presents Positive Phase 2 Imaging Data For XPro In Early Alzheimer's Disease At AAIC 2026(RTTNews) – INmune Bio Inc. (INMB), a late-stage biotechnology company focused on inflammation and immunology, announced new imaging data from its Phase 2 study of XPro in patients with early Alzheimer's disease. The results will be presented at the Alzheimer's Association Intern
- RTTNews · Jun 2, 10:05 AM EDTINmune Bio Reports Statistically Significant White Matter Biomarker Effect In Alzheimer's Trial(RTTNews) – INmune Bio Inc. (INMB) announced new exploratory MRI imaging from its Phase 2 MINDFuL trial of XPro in patients with early Alzheimer's disease, showing a statistically significant treatment effect on advanced white matter imaging biomarkers.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for INmune Bio Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.